Imlunestrant Tosylate

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameImlunestrant Tosylate
Drug Alias NameImlunestrant TosilateImlunestrantInluriyoLY-3484356
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors antagonists
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerHepatic InsufficiencyNeoplasm Metastasis +[7] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/09/25
Country/TerritoryCzechiaBelgiumCanada +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly Japan KkEli Lilly And CompanyEli Lilly Nederland BV +[5] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerHepatic InsufficiencyNeoplasm Metastasis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG